PER Intrinsic Valuation and Fundamental Analysis - Percheron Therapeutics Ltd

Watchlist Manager

Watchlist

Price: 0.0035 AUD -12.5% Market Closed

Market Cap: AU$5.3m

	Percheron Therapeutics Ltd ASX:PER	AU
M	Mida Assets PCL SET:MIDA	TH
	Kruk SA F:83I	PL
S	Sammakorn PCL SET:SAMCO	TH
	Van de Velde NV F:VO4	BE

Intrinsic Value

Is PER undervalued or overvalued?

See the intrinsic value estimate for Percheron Therapeutics Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

PER Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with PER’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Current Price AU$0

Intrinsic Value Locked

Margin of Safety 20% Locked

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Percheron Therapeutics Does

Pharmaceuticals Health Care

Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS).

Headquarters: Australia AU
IPO date: Dec 20, 2001